GSEP
CKPT

Golden State Equity Partners’s Checkpoint Therapeutics CKPT Stock Holding History

Golden State Equity Partners’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-340
Closed -$761 – 526
2024
Q3 		$761 Buy
+340
New +$785 ﹤0.01% 769
2022
Q1 		$24K Buy
1,335
+25
+2% +$537 0.01% 191
2021
Q4 		$41K Buy
+1,310
New +$43.4K 0.02% 170

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Golden State Equity Partners's CKPT Position: Q4 2024 in Review

Golden State Equity Partners sold out of Checkpoint Therapeutics (CKPT) in Q4 2024, closing a stake of 340 shares — an estimated $761 sold.

Golden State Equity Partners first reported a position in CKPT in Q4 2021 and held it in 3 quarters. The position peaked at $41K in Q4 2021. 68 funds tracked by Wall St. Rank hold CKPT as of Q4 2024.

  • Golden State Equity Partners reported no remaining Checkpoint Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 340 Checkpoint Therapeutics shares in Q4 2024, an estimated $761.
  • Golden State Equity Partners first reported a position in Checkpoint Therapeutics in Q4 2021 and held it in 3 quarters.
  • Golden State Equity Partners's Checkpoint Therapeutics position peaked at $41K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.